Looking for our Business Solutions? Click here:CloudQuote APIsContact Us
Home

Articles from MindWalk Holdings Corp.

MindWalk Reports Record Growth and Announces Strategic Progress on Its AI Asset Pipeline
MindWalk (NASDAQ: HYFT), a BioNative AI biotherapeutic research and technology company combining in silico and wet lab operations for biologics discovery and development, today announced financial results for the second quarter of fiscal 2026 and provided updates on its AI driven asset pipeline and strategic initiatives. MindWalk operates a proprietary BioNative AI platform built on patented HYFT® patterns—evolution shaped subsequence codes that link sequence, structure and function. These patterns underpin LensAI™, a software platform that harmonizes and analyzes diverse biological data to deliver actionable insights.
By MindWalk Holdings Corp. · Via Business Wire · December 15, 2025
MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2026 on December 15, 2025
MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for second quarter fiscal year 2026, on Monday, December 15, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. MindWalk management will host the conference call followed by a question-and-answer period.
By MindWalk Holdings Corp. · Via Business Wire · December 8, 2025
MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025
MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company, today announced that Dr. Dirk Van Hyfte, Chief Technology Officer, will participate in a fireside chat during the Biology Session at the AI Drug Discovery & Development Summit 2025, taking place on November 20, 2025, from 12:15 PM to 12:45 PM.
By MindWalk Holdings Corp. · Via Business Wire · November 13, 2025
MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy
MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), bio-native AI company today announces the appointment of industry veteran R. Scott Areglado as Chief Financial Officer (CFO), effective October 20, 2025.
By MindWalk Holdings Corp. · Via Business Wire · October 21, 2025
MindWalk Appoints Dr. Thomas W. Lynch as Chief Business Officer to Accelerate Commercial Expansion
MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company today announced the appointment of industry veteran Thomas W. Lynch, Ph.D. as Chief Business Officer (CBO), effective October 20, 2025.
By MindWalk Holdings Corp. · Via Business Wire · October 15, 2025
MindWalk Announces Share Repurchase Program
MindWalk Holdings Corp. (“MindWalk” or the “Company”) (NASDAQ: “HYFT”), a bio-native AI company, today announced that to underscore its confidence in MindWalk's future development and growth prospects, its Board of Directors (the “Board”) has authorized a share repurchase program under which MindWalk may repurchase up to 2.3 million common shares of the Company, no par value (the “Common Shares”) over the twelve-month period commencing on October 15th, 2025, and ending no later than October 15th, 2026 (the “Program”). This represents approximately 5% of the 46,154,188 Common Shares currently issued and outstanding.
By MindWalk Holdings Corp. · Via Business Wire · October 9, 2025
MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity
MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company, today announced a major advancement of its AI-designed GLP-1 therapeutics program. New insights from the Company’s LensAI™ platform reveal a previously unrecognized connection between GLP-1 biology and a second, non-overlapping pathway central to healthy aging and systemic resilience. The findings support a first-in-class dual-pathway regimen in which MindWalk’s proprietary companion therapeutic is co-administered with its GLP-1 receptor agonists (GLP-1RAs) to engage both mechanisms in concert. To the Company’s knowledge, no approved or marketed drugs use this regimen. The companion therapeutic is a MindWalk-exclusive asset and is not a repurposed or co-branded product.
By MindWalk Holdings Corp. · Via Business Wire · September 22, 2025
MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet
MindWalk Holdings Corp.™ (“MindWalk™”, “Company”, “we” or “us”) (NASDAQ: HYFT), a Bio-Native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced financial results for its first fiscal quarter of 2026, ended July 31, 2025. All numbers are expressed in Canadian dollars unless otherwise noted.
By MindWalk Holdings Corp. · Via Business Wire · September 15, 2025
MindWalk to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2026 on September 15, 2025
MindWalk (NASDAQ: HYFT) (“HYFT” or the “Company”), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year end 2026, on Monday, September 15, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. MindWalk management will host the conference call followed by a question-and-answer period.
By MindWalk Holdings Corp. · Via Business Wire · September 10, 2025